519 related articles for article (PubMed ID: 27167103)
1. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M
Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103
[TBL] [Abstract][Full Text] [Related]
2. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
Lopatin YM; Cowie MR; Grebennikova AA; Sisakian HS; Pagava ZM; Hayrapetyan HG; Abdullaev TA; Voronkov LG; Chesnikova AI; Tseluyko VI; Tarlovskaya EI; Dadashova GM; Berkinbaev SF; Glezer MG; Koziolova NA; Rakisheva AG; Kipiani ZV; Kurlyanskaya AK
Int J Cardiol; 2018 Jun; 260():113-117. PubMed ID: 29622423
[TBL] [Abstract][Full Text] [Related]
3. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
4. Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
Roth S; Fernando C; Azeem S; Moe GW
Adv Ther; 2017 Jun; 34(6):1340-1348. PubMed ID: 28432646
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
[TBL] [Abstract][Full Text] [Related]
6. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
7. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
[TBL] [Abstract][Full Text] [Related]
8. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
[TBL] [Abstract][Full Text] [Related]
9. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
10. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database.
Paolillo S; Mapelli M; Bonomi A; Corrà U; Piepoli M; Veglia F; Salvioni E; Gentile P; Lagioia R; Metra M; Limongelli G; Sinagra G; Cattadori G; Scardovi AB; Carubelli V; Scrutino D; Badagliacca R; Raimondo R; Emdin M; Magrì D; Correale M; Parati G; Caravita S; Spadafora E; Re F; Cicoira M; Frigerio M; Bussotti M; Minà C; Oliva F; Battaia E; Belardinelli R; Mezzani A; Pastormerlo L; Di Lenarda A; Passino C; Sciomer S; Iorio A; Zambon E; Guazzi M; Pacileo G; Ricci R; Contini M; Apostolo A; Palermo P; Clemenza F; Marchese G; Binno S; Lombardi C; Passantino A; Perrone Filardi P; Agostoni P
Eur J Heart Fail; 2017 Jul; 19(7):904-914. PubMed ID: 28233458
[TBL] [Abstract][Full Text] [Related]
12. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
13. Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine.
Raja DC; Kapoor A; Sinha A; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel P
Indian Heart J; 2018; 70(2):246-251. PubMed ID: 29716702
[TBL] [Abstract][Full Text] [Related]
14. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
Foster JL; Bobadilla RV
J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
[TBL] [Abstract][Full Text] [Related]
15. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of ivabradine in Chinese patients with chronic heart failure: an observational study.
Zhou J; Xu Y; Zheng Z; Zhang S; Yang J; Zhang Y; Tang B; Han H; Zhang Q; Liu F; Ding W; Qian C; Su G; Liu X; Shen Y; Shi B; Kong X; Ge Z; Zhang P; Guo X; Zhang H; Sun Y; Dong Y; Fu G; Feng L; Ge J;
ESC Heart Fail; 2024 Apr; 11(2):846-858. PubMed ID: 38193606
[TBL] [Abstract][Full Text] [Related]
18. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction.
Tóth N; Soós A; Váradi A; Hegyi P; Tinusz B; Vágvölgyi A; Orosz A; Solymár M; Polyák A; Varró A; Farkas AS; Nagy N
Can J Physiol Pharmacol; 2021 Nov; 99(11):1159-1174. PubMed ID: 34636643
[TBL] [Abstract][Full Text] [Related]
19. [Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction].
Kanorsky SG; Borisenko YV
Kardiologiia; 2016 Feb; 56(2):24-29. PubMed ID: 28294745
[TBL] [Abstract][Full Text] [Related]
20. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
